1. Home
  2. PNRG vs CINGW Comparison

PNRG vs CINGW Comparison

Compare PNRG & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PNRG
  • CINGW
  • Stock Information
  • Founded
  • PNRG 1973
  • CINGW N/A
  • Country
  • PNRG United States
  • CINGW United States
  • Employees
  • PNRG N/A
  • CINGW 13
  • Industry
  • PNRG Oil & Gas Production
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • PNRG Energy
  • CINGW Health Care
  • Exchange
  • PNRG Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • PNRG N/A
  • CINGW N/A
  • IPO Year
  • PNRG N/A
  • CINGW 2021
  • Fundamental
  • Price
  • PNRG $144.00
  • CINGW $0.05
  • Analyst Decision
  • PNRG
  • CINGW
  • Analyst Count
  • PNRG 0
  • CINGW 0
  • Target Price
  • PNRG N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • PNRG 86.3K
  • CINGW N/A
  • Earning Date
  • PNRG 05-19-2025
  • CINGW N/A
  • Dividend Yield
  • PNRG N/A
  • CINGW N/A
  • EPS Growth
  • PNRG 45.18
  • CINGW N/A
  • EPS
  • PNRG 21.32
  • CINGW N/A
  • Revenue
  • PNRG $240,956,000.00
  • CINGW N/A
  • Revenue This Year
  • PNRG N/A
  • CINGW N/A
  • Revenue Next Year
  • PNRG N/A
  • CINGW N/A
  • P/E Ratio
  • PNRG $6.77
  • CINGW N/A
  • Revenue Growth
  • PNRG 67.62
  • CINGW N/A
  • 52 Week Low
  • PNRG $103.51
  • CINGW N/A
  • 52 Week High
  • PNRG $243.49
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • PNRG 26.88
  • CINGW N/A
  • Support Level
  • PNRG $180.82
  • CINGW N/A
  • Resistance Level
  • PNRG $195.99
  • CINGW N/A
  • Average True Range (ATR)
  • PNRG 9.96
  • CINGW 0.00
  • MACD
  • PNRG -4.61
  • CINGW 0.00
  • Stochastic Oscillator
  • PNRG 9.26
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: